- Home
- LEO vs HUMA Comparison
LEO vs HUMA Comparison
Compare LEO & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEO
- HUMA
- Stock Information
- Founded
- LEO 1987
- HUMA 2004
- Country
- LEO United States
- HUMA United States
- Employees
- LEO N/A
- HUMA N/A
- Industry
- LEO Trusts Except Educational Religious and Charitable
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- LEO Finance
- HUMA Health Care
- Exchange
- LEO Nasdaq
- HUMA Nasdaq
- Market Cap
- LEO 391.2M
- HUMA 427.2M
- IPO Year
- LEO N/A
- HUMA N/A
- Fundamental
- Price
- LEO $6.17
- HUMA $1.49
- Analyst Decision
- LEO
- HUMA Strong Buy
- Analyst Count
- LEO 0
- HUMA 6
- Target Price
- LEO N/A
- HUMA $14.60
- AVG Volume (30 Days)
- LEO 200.2K
- HUMA 5.2M
- Earning Date
- LEO 01-01-0001
- HUMA 03-28-2025
- Dividend Yield
- LEO 4.01%
- HUMA N/A
- EPS Growth
- LEO N/A
- HUMA N/A
- EPS
- LEO 0.04
- HUMA N/A
- Revenue
- LEO N/A
- HUMA N/A
- Revenue This Year
- LEO N/A
- HUMA N/A
- Revenue Next Year
- LEO N/A
- HUMA $1,217.58
- P/E Ratio
- LEO $152.00
- HUMA N/A
- Revenue Growth
- LEO N/A
- HUMA N/A
- 52 Week Low
- LEO $4.98
- HUMA $1.31
- 52 Week High
- LEO $6.50
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- LEO 50.00
- HUMA 22.36
- Support Level
- LEO $6.07
- HUMA $1.96
- Resistance Level
- LEO $6.35
- HUMA $3.36
- Average True Range (ATR)
- LEO 0.06
- HUMA 0.26
- MACD
- LEO -0.00
- HUMA -0.13
- Stochastic Oscillator
- LEO 68.75
- HUMA 8.74
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others. BNY Mellon and its affiliates, including BNYM Investment Adviser, INA and others involved in the management, sales, investment activities, business operations or distribution of the Fund, are engaged in businesses and have interests other than that of managing the Fund.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.